Drug intelligence / Profile preview

PMI-001

Development stage: Unknown
Lead developer: Phytomedics
Modality: Small Molecules
Administration: Oral

Overview

PMI-001 is a plant-derived, orally bioavailable, small-molecule disease-modifying anti-rheumatic drug (DMARD) developed by Phytomedics. It is an extract from the roots of an undisclosed perennial shrub and acts as a multi-component agent. The mechanism of action involves interference with the production of interleukin-2 (IL-2) and cyclooxygenase-2 (COX-2), as well as inhibition of IL-1β, inducible nitric oxide synthase (NOS2), and tumor necrosis factor-alpha (TNF-α). These actions are intended to modulate immune responses and inflammation for the potential treatment of autoimmune diseases such as rheumatoid arthritis, lupus erythematosus, and psoriasis.

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)TNFA (Tumor necrosis factor alpha (soluble))IL-2 (Interleukin 2)NOS2 (Nitric Oxide Synthase 2)IL1B (Interleukin-1 beta)

Beyond the preview

Go deeper on PMI-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PMI-001.

Explore the full profile